Craig Thompson's Appointment Marks a Strategic Move for Esperion
Esperion Therapeutics, Inc., renowned for its innovative biopharmaceutical advancements, has made a significant stride in expanding its Board of Directors. The company proudly announced the appointment of Craig Thompson, the Chief Executive Officer of Cerevance, as an independent director. With this new addition, Esperion's board now boasts eight members, potentially enhancing its strategic capabilities.
Strengthening Leadership in Cardiovascular Health
Sheldon Koenig, President and CEO of Esperion, expressed enthusiasm about having Thompson on board. With over two decades of experience in the biopharmaceutical industry, Thompson brings invaluable expertise and leadership. His appointment aligns with Esperion's commitment to advancing innovations in cardiovascular and cardiometabolic drug development. Koenig highlighted Thompson's substantial understanding of pharmaceutical commercialization and clinical development as crucial assets for the company’s ongoing mission to deliver life-saving solutions worldwide.
A Vision for Future Innovations
In his acceptance, Thompson remarked on the honor of joining Esperion's board at a crucial time. He pointed out the urgent need for innovative cardiovascular solutions, given that such conditions are the leading cause of death around the globe. Thompson expressed his eagerness to collaborate with the talented team at Esperion to guide strategic decisions and accelerate the development of impactful, science-driven therapies that could significantly improve quality of life for many patients.
Craig Thompson's Impressive Career Background
Before joining Esperion, Craig Thompson held the position of CEO at Cerevance, a clinical-stage biotechnology firm concentrating on neurodegenerative and psychiatric disorders. He has also served on the boards of companies focused on neurological therapy development, which adds depth to his expertise. Between 2018 and 2022, he was at the helm of Neurana Pharmaceuticals, helping steer its development initiatives. His previous experience includes significant roles at Anthera Pharmaceuticals, Tetraphase Pharmaceuticals, and Trius Therapeutics. At Trius, he played a pivotal role in a massive acquisition that showcased his strategic and commercial acumen.
A Wealth of Experience from Pfizer and Merck
Thompson's vast experience extends to leadership roles at Pfizer, where he drove marketing strategies for several therapeutic areas. His tenure at Merck saw him deeply involved in the management of major cholesterol-lowering medications, signifying his long-standing involvement in critical healthcare solutions.
Educational Qualifications
Thompson's educational achievements include a Bachelor of Commerce degree from McMaster University and an MBA from the prestigious University of Notre Dame, which further solidifies his qualifications for the role.
About Esperion Therapeutics
Esperion Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing new medications that meet the needs of patients with cardiovascular issues. The company has successfully developed the first and only FDA-approved oral, once-daily, non-statin medications for those at risk of cardiovascular disease. These efforts are backed by the extensive CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients. Esperion aims to enhance its successful legacy by venturing into novel drug development pathways focused on creating ATP citrate lyase inhibitors (ACLYi), known for their promise in treating cholesterol-related conditions.
Committed to Global Biopharmaceutical Leadership
As Esperion continues on its innovative journey, it seeks to evolve into a prominent global biopharmaceutical entity through strategic commercial execution and global partnerships while advancing its promising pre-clinical pipeline. For inquiries or more information about the company, please reach out to the contact details below.
Esperion Contact Information
Investors: Alina Venezia
(734) 887-3903
investorrelations@esperion.com
Media: Tiffany Aldrich
(616) 443-8438
corporateteam@esperion.com
Frequently Asked Questions
What prompted Craig Thompson's appointment to Esperion?
Craig Thompson's appointment is part of Esperion's strategy to enhance its leadership in cardiovascular health and innovation.
What is the expertise that Craig Thompson brings to Esperion?
Thompson brings over 20 years of biopharmaceutical leadership, particularly in cardiovascular drug development and commercialization.
How does Esperion plan to innovate under Thompson's leadership?
Esperion aims to leverage Thompson's insight to expedite strategic decisions and develop impactful therapies for cardiovascular disease.
What significant roles has Thompson held in the past?
Thompson has served as CEO in several biotech firms and held leadership positions at Pfizer and Merck, showcasing his extensive experience.
How can investors contact Esperion for inquiries?
Investors can contact Esperion through Alina Venezia at (734) 887-3903 or via email at investorrelations@esperion.com.
